Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Zhongda Hospital is the lead sponsor of 29 current clinical trials in our China register. 16 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Propranolol, Roxadustat and Saccharomyces boulardii. The most-studied condition is Unresectable Hepatocellular Carcinoma.

ClinicalTrials.gov trials by status

Recruiting1655%
Not yet open828%
Active, closed517%

Trials by phase

Observational1448%
Not applicable1345%
Phase 1/227%

Clinical trials sponsored by Zhongda Hospital

29 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Epidural Spinal Cord Stimulation for Respiratory Recovery in Cervical SCI NCT07722130 · ClinicalTrials.gov ↗ · Spinal Cord Injury Cervical, Respiratory Failure	Not applicable	Recruiting	2026-06	China
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis NCT07573735 · ClinicalTrials.gov ↗ · Atopic Dermatitis (Eczema)	Observational	Recruiting	2026-02	China
PyroEVs/PLIN3 Mediate Lipid Droplet-Mitochondrial Coupling in Sepsis Endothelial Injury NCT07727265 · ClinicalTrials.gov ↗ · Sepsis	Observational	Recruiting	2024-07	China
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma NCT06694636 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2024-02	China
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study NCT06849193 · ClinicalTrials.gov ↗ · Unresectable Biliary Tract Cancer, Dynamic Prediction Model, Immunotherapy	Observational	Recruiting	2025-01	China
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data NCT06849180 · ClinicalTrials.gov ↗ · Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma	Observational	Recruiting	2024-12	China
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma NCT07351669 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT	Observational	Recruiting	2026-01	China
Sigh Ventilation in Cardiac Surgery NCT07024420 · ClinicalTrials.gov ↗ · Postoperative Pulmonary Complications (PPCs), Cardiac Surgery in Adult Patient	Not applicable	Recruiting	2025-10	China
Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability NCT07504731 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome (ARDS)	Observational	Recruiting	2026-03	China
Therapeutic Effect of Electroacupuncture at Zusanli (ST-36) on Diabetic Foot Wounds NCT07482137 · ClinicalTrials.gov ↗ · Diabetes Foot Care	Not applicable	Recruiting	2025-07	China
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. NCT06669377 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Observational	Recruiting	2024-01	China
TACE With Thermosensitive Nanogel Versus Embosphere for HCC NCT06593964 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Not applicable	Recruiting	2024-09	China
SIRT Versus cTACE for Unresectable HCC (CHANCE2506) NCT06909708 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Not applicable	Recruiting	2025-04	China
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2018-06	China
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC NCT06190665 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2023-12	China
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability NCT06430554 · ClinicalTrials.gov ↗ · Respiratory Distress Syndrome, Positive-Pressure Respiration, Mechanical Ventilation	Observational	Recruiting	2024-06	China
AI Assistance for Detecting Active Bleeding During DSA Procedures NCT07824739 · ClinicalTrials.gov ↗ · DSA, Bleeding, AI (Artificial Intelligence)	Not applicable	Not yet open	2026-10	China
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection NCT07012785 · ClinicalTrials.gov ↗ · H. Pylori Infection Drug: Saccharomyces boulardii	Not applicable	Not yet open	2025-06	China
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease NCT07268807 · ClinicalTrials.gov ↗ · Heart Failure, CKD, Anemia Drug: Roxadustat	Observational	Not yet open	2025-12	China
Early Electroacupuncture for Post-TURP LUTS NCT07736807 · ClinicalTrials.gov ↗ · Benign Prostatic Hyperplasia	Not applicable	Not yet open	2026-07	China
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial NCT07187284 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 1/2	Not yet open	2025-09	China
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study NCT07311915 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: Propranolol	Not applicable	Not yet open	2026-01	China
Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026) NCT07824765 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Observational	Not yet open	2026-09	China
Epidural Spinal Cord Stimulation for Respiratory Recovery in Brain Injury NCT07766681 · ClinicalTrials.gov ↗ · Brain Injuries, Respiratory Failure	Not applicable	Not yet open	2026-08	China
The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury NCT07602465 · ClinicalTrials.gov ↗ · Acute Kidney Injury (AKI)	Observational	Active, closed	2026-06	China
Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer NCT05963100 · ClinicalTrials.gov ↗ · Safety and Efficacy of TCR-like CAR-T	Phase 1/2	Active, closed	2023-08	China
Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression NCT07585877 · ClinicalTrials.gov ↗ · Myopia Progressing, Myopia	Not applicable	Active, closed	2026-01	China
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy NCT07065786 · ClinicalTrials.gov ↗ · Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma	Observational	Active, closed	2024-01	China
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001) NCT07204327 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Observational	Active, closed	2020-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Zhongda Hospital trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Propranolol1 Roxadustat1 Saccharomyces boulardii1

Conditions in Zhongda Hospital trials

39 conditions

Unresectable Hepatocellular Carcinoma5 Hepatocellular Carcinoma3 Respiratory Failure2 HCC - Hepatocellular Carcinoma2DSA1Bleeding1AI (Artificial Intelligence)1Hemorrhage1Acute Kidney Injury (AKI)1Spinal Cord Injury Cervical1H. Pylori Infection1Heart Failure1CKD1Anemia1Atopic Dermatitis (Eczema)1Safety and Efficacy of TCR-like CAR-T1Sepsis1Unresectable Biliary Tract Cancer1Dynamic Prediction Model1Immunotherapy1Myopia Progressing1Myopia1Combined Hepatocellular-cholangiocarcinoma1Combined Hepatocellular Carcinoma and Cholangiocarcinoma1

By trial register

Register	Trials	Recruiting
Clinical trials in China	29	16

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Unresectable Hepatocellular Carcinoma

Sponsor	Trials
Zhiyong Huang	2
Chengdu New Radiomedicine Technology	1

Sponsors with the most current trials registered for this condition.

Questions about Zhongda Hospital trials

How many clinical trials does Zhongda Hospital sponsor?

Zhongda Hospital is the lead sponsor of 29 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhongda Hospital trials recruiting?

Yes. 16 of its 29 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhongda Hospital testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Propranolol (1), Roxadustat (1) and Saccharomyces boulardii (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Zhongda Hospital clinical trials